Building a Better Cell Therapy CDMO

Potency Assurance

Why Potency Cannot Be Reduced to a Release Assay in Active Immunotherapy Development

David Alvaro, Ph.D.

Pharma's Almanac

ATMP Supply Chain

Maintaining Resilient Supply Chains for Advanced Therapies

Pharma's Almanac

In Vivo CAR-T

Five Companies Bringing In Vivo CAR-T Therapy Closer to the Clinic

Emma Gormlie

Nice Insight

Stem Cells

Stem Cell Therapies: Close to Transforming Promise into Real Patient Outcomes

Cynthia A. Challener, Ph.D.

Pharma's Almanac

In Vivo Selection

Repairing More Tissue Than You Edit: What In Vivo Selection Could Mean for Gene Therapy

David Alvaro, Ph.D.

Pharma's Almanac

Genome Engineering

Aiming for More than Single-Base Corrections: The Technologies Opening the Genome to Therapeutic Cargo

David Alvaro, Ph.D.

Pharma's Almanac

Microbiome Editing

Editing the Microbiome in Place: From Engineered Probiotics to Programmable Ecological Therapies

David Alvaro, Ph.D.

Pharma's Almanac

Pathfinder

Lipid Nanoparticles vs. Viral Vectors for Gene Delivery: Which Platform Is Better?

Nice Insight

Continuous VV

The Stepwise Future of Continuous Viral Vector Manufacturing

David Alvaro, Ph.D.

Pharma's Almanac

Pathfinder

AAV vs. Lentiviral Vectors: Which Viral Vector Is Better for Gene Therapy?

Nice Insight

Roundtable

How is the increasing complexity of modalities reshaping CDMO differentiation and specialization strategies?

Pharma's Almanac